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Introduction {#sec1}
============

An ideal tumor-targeted contrast agent should have high uptake and prolonged retention in malignant tissue as well as minimum uptake and fast clearance from surrounding normal tissues ([@bib10], [@bib28]). The most common tumor targeting strategy is to conjugate a targeting ligand (e.g., small molecule, peptide, peptidomimetic, or protein) to a contrast agent ([@bib9]). Targeted delivery of a specific agent to the cancerous tissue is significant for oncologists to plan a treatment strategy as well as for surgeons to decide the surgical margin based on image guidance ([@bib18], [@bib20]).

The resection of pancreatic neuroendocrine tumor (PNET) and the avoidance of normal pancreas represent a significant unmet clinical need. Currently, intraoperative visual inspection and palpation performed by the surgeon is considered the most reliable source for PNET detection, which often results in incomplete resection of the tumor, with 5-year disease recurrence rate of 10% and 97% of patients without and with liver metastasis, respectively ([@bib26], [@bib22], [@bib23], [@bib29]). Therefore, complete tumor resection remains the only treatment option that improves patient survival ([@bib36], [@bib26]).

Significant efforts have been focused on improving preoperative and intraoperative identification of tumors and their margins; however, it presents a major challenge to detect PNET with sufficient sensitivity ([@bib14], [@bib12]). Conventional preoperative techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasonography are successful in localizing larger tumors, although detection is very challenging for subcentimeter lesions with a broad-ranged sensitivity (9.6%--71%) ([@bib12]). Undetectable small-size PNET can cause severe symptoms of hormonal imbalance such as hypoglycemia or hyperglucagonemia due to excess production of insulin or glucagon, respectively. To increase small tumor detection, glucagon-like peptide-1 (GLP-1) radioligands were developed to diagnose PNET with highly expressed GLP-1 receptors on beta-cells, yet detecting tumors \<2 cm remains elusive ([@bib30], [@bib34]).

Near-infrared (NIR) fluorescence imaging has the potential to improve the detectability and spatial resolution significantly ([@bib17], [@bib16], [@bib27]). Currently, only two small NIR fluorophores, methylene blue (MB) and indocyanine green (ICG), have been FDA approved for tumor imaging in the clinics without clarifying the mode of action ([@bib33], [@bib1]), resulting in low tumor-to-background ratio (TBR). Previously, MB was used for detecting insulinoma, the most common functioning PNET, using optical imaging ([@bib35]). However, due to its poor optical properties (i.e., low molecular brightness), rapid clearance from the body, and chemical reduction, MB is not ideal for intraoperative tumor targeting. Therefore, bioengineering of a single NIR small fluorophore to target such a tiny neoplasm is of significant importance with improved specificity and biodistribution ([@bib15], [@bib7]).

The delivery and retention of a molecule in tumor tissue is dependent on the size, charge, hydrophobicity, pharmacodynamics, pharmacokinetics, and its transport across the tumor vasculature ([@bib19], [@bib21]). However, the physicochemical properties of cancer-targeting fluorophores are not well established. In the present study, we have developed a lead PNET-targeted, phenoxazine-based NIR fluorescent contrast agent by analyzing the biodistribution of a small fluorophore library with the potentials to accumulate into PNET using insulinoma-bearing transgenic mice. Thereby, we have determined bioengineering of the physicochemical properties, and pharmacokinetics is required to achieve the specific targeting for PNET that can provide image guidance needed during the tumor resection.

Results {#sec2}
=======

Systemic Modification for Development of PNET Targeting NIR Fluorophore {#sec2.1}
-----------------------------------------------------------------------

MB is the first and the only NIR fluorophore used for intraoperative localization of PNET ([@bib35]). However, when MB is administrated intravenously into the body, approximately 75% is reduced to leuco-MB in erythrocytes via the endogenous reductase by consuming NADPH and loses fluorescence ([@bib25], [@bib4], [@bib5], [@bib24]). Despite these limitations of MB as an endocrine tumor imaging agent, we still believed that the core structure of the MB holds the key properties for the initial accumulation into the tumor and hypothesized that systematic modification of MB could potentially improve its optical and biological characteristics.

Therefore, we first focused on enhancement of optical properties and *in vivo* stability of MB. Among several different substitutions of the MB core (data not shown), we found that substitution of the sulfur atom of MB with oxygen resulted in the most improvement in both optical and biological properties ([Figure 1](#fig1){ref-type="fig"}A). With this first modification, we named the molecule Ox61 (see [Transparent Methods](#mmc1){ref-type="supplementary-material"} and [Figures S1--S5](#mmc1){ref-type="supplementary-material"}). The single oxygen substitution in Ox61 led to hypsochromic shift and 5.7-fold brightness increase compared with MB: 1.3-fold increase in molecular absorbance (*Δε* = 12,300 M^−1^cm^−1^) and 4.5-fold increase in quantum yield (*ΔΦ* = 8.6%), respectively ([Figures 1](#fig1){ref-type="fig"}B--1D) ([@bib5]).Figure 1PNET-Specific Fluorescent Agents MB and Ox61(A) Schematic drawing of PNET targeting by NIR fluorophores: MB converts to colorless leucomethylene blue (LMB) in erythrocytes, whereas oxygen substation become inert from redox mechanisms in the body.(B and C) (B) Comparison of optical properties: absorbance (solid line: left axis) and fluorescence emission (dotted line: right axis) spectra (C) optical properties measured in 100% serum, pH 7.0.(D) Fluorescence imaging of difference concentration of MB and Ox61.(E) Live cell binding assay: 2 μM of MB or Ox61 was incubated for 1 h with NIT-1 (pancreatic beta cell) and α-TC1 (pancreatic alpha cell) cell lines, followed by treatment with 0.1 mM of periodic acid to induce oxidation. Scale bar, 50 μm.

To show high redox stability toward biological reduction after oxygen substitution, we performed an *in vitro* live cell assay to evaluate the cellular specificity by comparing MB and Ox61 in NIT-1 (pancreatic β-cell). Both MB and Ox61 stained the NIT-1 cells; however, Ox61 showed a significantly higher signal compared with MB ([Figure 1](#fig1){ref-type="fig"}E, *P*\<0.05). We subsequently treated the membrane-stained cells with 0.1 mM periodic acid to test the presence of the leuco form of both fluorophores. Interestingly, the fluorescence signal of MB inside NIT-1 cells was recovered by oxidation, whereas no notable changes were observed in the Ox61 stained cells, which remained high pre- and post-treatment. Similarly, we also treated periodic acid on the kidneys resected from normal CD-1 mice 1 h after injecting 1.5 mg/kg of MB or Ox61 intravenously. The fluorescence signal significantly increased in the MB-injected mouse kidney, whereas no intensity changes were found in the Ox61-injected mouse kidney ([Figure S6](#mmc1){ref-type="supplementary-material"}, *P*\<0.0001). This indicates that MB is reduced to LMB by endogenous reductase, but Ox61 is stable from the redox cycle and retains strong fluorescence signal.

Structural Characterization of PNET Targeting NIR Fluorophore {#sec2.2}
-------------------------------------------------------------

After the first modification and the improvement in optical properties and biological stability, we then synthesized 18 additional phenoxazine derivatives by varying side chains ([Figure 2](#fig2){ref-type="fig"}A). To test the tumor targetability of these derivatives, 1.5 mg/kg of each molecule was injected intravenously into the insulinoma bearing mice and imaged 30 min after injection under the FLARE intraoperative optical imaging system ([Figure S7](#mmc1){ref-type="supplementary-material"}A) ([@bib13]). Physicochemical properties and tumor-to-background ratio (Tu/Pa) of MB and molecules in PNET library are summarized in [Table 1](#tbl1){ref-type="table"}. Among the 19 contrast agents, four (Ox61, 89, 261, and 266) had TBR \>2.0 and only Ox61 had TBR \>5.0. We then analyzed the quantitative physicochemical properties of the molecules to define the criteria required for PNET targetability. Molecular weight (MW), hydrophobicity, and total polar surface area of each agent were plotted in a chart, and Ox61 was labeled with red (TBR \>5.0), MB with blue, molecules with TBR above 2 with orange, and the rest with dark gray ([Figure 2](#fig2){ref-type="fig"}B). Based on the chart, we were able to determine the PNET targetability range for each chemical property (red margin), and if the molecule did not fall within the optimal range, it had low or no tumor targetability. In summary, highly hydrophilic molecules with low molecular weight (\<300 Da) and low TPSA (\<40) had suitable accumulation in PNET. In addition, positive charge of the molecule favored tumor accumulation. Another interesting observation was that change in hydrophobicity of the molecule with elongation of side chain dramatically altered tumor targetability ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Other critical factors influencing tumor targeting are the plasma pharmacokinetics of probe residence in the circulation and diffusivity of the molecule across tumor vasculature into the extravascular tissue^25,26^ ([@bib11]). To evaluate the probe transport in circulation, we performed plasma protein binding test using the rapid equilibrium dialysis (RED) to determine the free (%Fu) and bound (%Bound) fraction of drugs in plasma. As a result, Ox61 with the highest tumor uptake had the least plasma protein bound fraction (45% bound) and the Ox89, 261, and 266 with TBR around 2 also had (\<50%--70% bound), which is relatively low compared with the rest of the drugs with low or no tumor uptake (90%--100% bound) ([Table 1](#tbl1){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}B). These results indicate that low plasma binding favors tumor targeting, which would prevent sequestration of a probe to plasma compartment.Figure 2PNET-Specific Fluorescent Small Molecule Library(A) Molecular structure of PNET-specific fluorophores.(B) Quantitative calculation of molecular weight (MW), log*D*, TPSA, and plasma protein % bound.Table 1*In Silico* Physicochemical Properties of PNET-Targeted Contrast AgentsDrugMW (g/mol)Log D (pH = 7.4)TPSA (Å^2^)HBAVolume (Å^3^)Dipole (Debye)Polarizability (Cm^2^ V^−1^)Plasma (% Bound)Tumor IntensityMB284.40−0.6218.612387.929.4832.7481.92+++Ox61268.34−1.0927.843382.049.3830.3445.87+++++Ox89282.370.4138.803414.9610.3932.1866.59+++Ox261296.39−0.3827.843447.638.2434.0365.82+++Ox266294.38−0.2727.843420.297.9733.3052.01+++Ox4296.400.7047.593442.8810.8733.9568.84++Ox14318.400.5159.213449.609.6636.3996.42++Ox17379.390.7163.314442.3610.4635.5795.06++Ox94324.451.6647.593504.257.7937.6482.91++Ox12304.370.0959.213416.5110.3734.5594.22+Ox116334.40−0.0668.444434.5211.4337.0697.73+Ox117348.430.9156.824499.1710.2238.9086.13+Ox170332.431.6547.593483.618.6438.2496.92+Ox269308.400.1827.843447.787.0035.1481.28+Ox13320.371.1579.444427.669.8035.1488.98--Ox16334.401.6270.654460.0512.8037.0687.62--Ox27456.541.38114.027631.8611.8747.3095.48--Ox37450.170.63123.256606.7522.0746.0073.12--Ox34450.451.05114.737604.3611.9045.0882.91--Ox96324.450.3327.843508.5674.7237.7281.45--[^3]

Kinetics and Dose Dependence of Ox61 {#sec2.3}
------------------------------------

Because MB is the only available PNET contrast agent, we compared results directly obtained with the lead compound Ox61 with MB. We first compared *in vivo* biodistribution and clearance pattern in normal CD-1 mice 4 h after a single intravenous injection of Ox61 or MB ([Figure S8](#mmc1){ref-type="supplementary-material"}). The pattern for biodistribution and renal excretion was almost identical, but the fluorescence signal in the Ox61 injected mice was about 2- to 5-fold higher than MB injected mice. We also compared *in vivo* biodistribution and blood clearance and found that Ox61 had prolonged blood circulation compared with MB. In these comparisons, we excluded the measurement of leuco-MB form to make a direct comparison with Ox61 for their *in vivo* fluorescence signals. The elimination blood half-life (*t*~1/2β~) of Ox61 was 3-fold longer than that of MB (47 versus 15 min) in mice ([Figure 3](#fig3){ref-type="fig"}A). We next performed a wide range of dose tests between 0.3 and 6.0 mg/kg. Although the lowest dose of 0.3 mg/kg resulted in improved TBR compared with MB, substantial signal increase in tumors occurred with 1.5 mg/kg and 3.0 mg/kg of Ox61, which showed much higher TBR compared with MB ([Figure 3](#fig3){ref-type="fig"}B, *P*\<0.001). Tumor signals were further increased when injected with the maximum dose of 6.0 mg/kg, but the background signal in pancreas also increased, which lowered the TBR between 1 h and 4 h. To determine the optimum time point for tumor targeting, we injected 1.5 mg/kg of Ox61 or MB into insulinoma-bearing mice and observed the TBR change over 4 h post-injection. In both cases, tumors became bright immediately after injection ([Figure 3](#fig3){ref-type="fig"}C). However, the pattern of uptake and retention at the tumorous tissue was notably different between Ox61 and MB. Ox61 gradually accumulated into insulinomas over 3 h post-injection, whereas MB rapidly disappeared within 1 h. The peak TBR of Ox61 occurred 3--4 h post-intravenous injection, at which point surrounding background signal had decreased drastically.Figure 3Intraoperative Imaging and Image-Guided Resection of PNET(A) Blood half-life (%ID/g) of each compound in mice was calculated using the nonlinear regression two-phase exponential decay method.(B) Dose-response curve of TBR (mean ± SEM) for MB (blue) and Ox61 (red). Different doses of each fluorophore were injected intravenously into insulinoma mice, and TBR (Tu/Pa) was quantified.(C) Quantitative time course assessment of TBR (mean ± SEM) for MB (blue) and Ox61 (red) for 4 h after a single bolus injection (1.5 mg/kg) of each fluorophore.(D) 1.5 mg/kg of MB or Ox61 was injected into 14-week-old insulinoma-bearing mice 4 h prior to imaging. Shown are occult and ectopic tumor metastases using NIR fluorescence.(E) Image-guided tumor resection after intraoperative tumor imaging and tumors at each stage were resected 4 h post-injection of Ox61 (1.5 mg/kg) and quantified (n = 5, mean ± s.d.). All NIR fluorescence images for each condition have identical exposure times and normalizations. Scale bars, 1 mm.(F) Histological evaluation of different stages of tumors in insulinoma-bearing pancreas. Shown are H&E and 700 nm NIR fluorescence (Ox61) of three different stages of resected tumors. Insulinoma stage of tumor showed presence of normal (arrow) and squeezed (arrowhead) vasculature. All NIR fluorescence images for each condition have identical exposure times and normalizations. I, insulinoma; E, exocrine pancreas. Scale bars, 100 μm

Tumor Targetability and Specificity of Ox61 {#sec2.4}
-------------------------------------------

Having determined optimal kinetics and dose, we tested the effect of physiological changes from tumor developmental stage on Ox61 uptake and retention. Small occult PNET (\<2 mm) are extremely difficult to localize and cannot typically be visualized in the surgical field. When insulinoma-bearing mice were injected with Ox61, however, small occult tumors were clearly visualized throughout the pancreas ([Video S1](#mmc2){ref-type="supplementary-material"}). In contrast, similar tumors were not detectable at 4 h post-injection of MB because of its fast elimination, leuco-MB formation, and poor optical properties ([Figure 3](#fig3){ref-type="fig"}D). After a single intravenous injection of Ox61, we successfully resected five different developmental stages of tumorigenesis under fluorescence image guidance with high TBR (tumor to pancreas) ([Figure 3](#fig3){ref-type="fig"}E). Because MRI has been used previously to monitor tumor growth, we compared tumor detectability with intraoperative fluorescence imaging. MRI visualized both hyperintense (early stage) and isointense (late stage) of larger sized tumors (\>2 mm) of 13-week-old insulinoma mouse, yet delineating tumor margins was a challenge. After injection of 1.5 mg/kg of Ox61 into the same mouse, we obtained intraoperative fluorescence images co-registered with the MR images ([Figure S9](#mmc1){ref-type="supplementary-material"}A). Dual-modality imaging permitted clearer margin assessment; however, fluorescence imaging revealed additional small tumors that were not detectable by MRI.

Video S1. Real-Time Intraoperative Imaging of Insulinomas Using Ox61 for 2 min Post-injection, Related to Figure 3

Next, we tested the effect of physiological change in tumor stages on Ox61 accumulation. PNET stages are well defined in transgenic mice: pre-angiogenic/hyperplasia (5--6 weeks), angiogenic/dysplasia (7--9 weeks), early stage tumors (10--11 weeks), mature stage tumors (11--13 weeks), and necrotic tumors (\>13 weeks) ([@bib3]). We performed Ox61-based tumor imaging in 5- to 13-week-old insulinoma-bearing mice ([Figure S9](#mmc1){ref-type="supplementary-material"}B). Surprisingly, Ox61 was able to target and localize pre-angiogenic tumors in mice with a reliable TBR ≥2.0 but short retention time compared with angiogenic and tumor stage. Histopathologic evaluation was performed on resected tumor tissues, which confirmed the morphological changes of tumors at each stage ([Figure 3](#fig3){ref-type="fig"}F). Despite the heterogeneity nature of pancreatic endocrine tumorigenesis, the efficient uptake of Ox61 at all stages of tumors was observed. Hyperplasia stage and angiogenic stage tissues showed homogeneous fluorescence signal at the tumor site, whereas Ox61 uptake in the late stage of PNET was heterogeneous because, presumably, of limited blood supply. Areas around open vasculature exhibited more favorable accumulation of Ox61 compared with other areas with compressed vasculature (arrowheads).

Physiological Mechanism of Action of Ox61 {#sec2.5}
-----------------------------------------

To better understand the physiological mechanism of Ox61 accumulation at the tumor site, we measured absolute fluorescence intensity at the pancreas and the tumor from 0 to 150 s post-injection of 1.5 mg/kg of Ox61 and corresponding images at four different time points on the graph ([Figure 4](#fig4){ref-type="fig"}A). The entire pancreas and its associated tumors were stained with high intensity immediately after the injection. Both pancreas and tumors showed decrease in signal after reaching the peak of the blood distribution phase (phase 2). Interestingly, the signal intensity in the tumor increased gradually after a short period of clearance, whereas the pancreas signal continued to decrease (phase 3--4). This phenomenon clearly demonstrates the high specificity of Ox61 to tumor site. The distribution of tumor-targeting probe is dependent on the transport through tumor vasculature into the extravascular tissue ([@bib11]). For further analysis of the diffusion of the Ox61 from the tumor capillaries, we performed real-time, quantitative intravital fluorescence imaging. Within 10 s after the injection a large amount of Ox61 diffused from microvasculature of the tumor followed by rapid accumulation in all tumorous tissues as well as large venules ([Figure 4](#fig4){ref-type="fig"}B). We next compared the performance of Ox61 with various tumor-specific protein-conjugated fluorophores (GLP-1, cRGDyK, and CREKA micelle, see [Transparent Methods](#mmc1){ref-type="supplementary-material"}), which are known to have high specificity to tumors ([@bib9], [@bib34], [@bib31]). None of these conjugates were able to target a single tumor in insulinoma-bearing mice 1 h post-injection ([Figure S10](#mmc1){ref-type="supplementary-material"}A). In addition, we tested tumor cell specificity of Ox61 by generating NIT-1 subcutaneous tumor in nude mice and injected with 1.5 mg/kg of Ox61 but were not able to observe accumulation into the tumor ([Figure S10](#mmc1){ref-type="supplementary-material"}B).Figure 4Extravasation and Tumor Uptake of Ox61 across Tumor Microvasculature(A) Kinetics and representative intraoperative images for signal uptake in pancreas and PNET: (1) pre-injection, (2) circulation, (3) initial uptake, and (4) accumulation and retention. In, intestine; Ki, kidneys; Pa, pancreas.(B) Representative intravital microscopic images with real-time quantification of the extravasation rate after a single intravenous injection of Ox61. Microvasculature was labeled with FITC-dextran (green color) 10 min prior to intravenous injection of Ox61 (red color). White dotted circles indicate PNET; scale bar, 200 μm.

Discussion {#sec3}
==========

We have successfully developed a pancreatic tumor-targeted contrast agent, Ox61, through systemic engineering of a clinically available, yet poorly performing NIR fluorophore, MB, for intraoperative imaging ([@bib35], [@bib24]). Ox61 has overcome historical shortcomings of NIR fluorophores, including low water solubility, short circulation time, low quantum efficiencies, poor photostability, high plasma protein binding rate, and low TBR ([@bib8]). Ox61 has improved molecular brightness (\>5-fold), redox stability, blood circulation (\>3-fold), and targeting specificity (\>10-fold) compared with MB. The improvement in optical properties resulted from (1) high oscillator strength derived from the larger atom size (covalent radius of atom: S = 0.104 nm versus O = 0.066 nm), (2) low-energy π-π∗ transition donating electron density (electronegativity: S = 2.4 versus O = 3.5), and (3) low solvation energies in polar media (HBA: S = 2 versus O = 3) ([@bib5]).

Our data clearly indicate that design of a tumor-targeting fluorophore requires a specific combination of physicochemical properties of the molecule. By analyzing quantitative physicochemical properties of synthesized molecules ([Figure 2](#fig2){ref-type="fig"}A), we have determined that specificity to tumor is highly dependent on the chemical structure, MW, hydrophilicity (log*D* at pH 7.4), and total polar surface charge ([Figure S8](#mmc1){ref-type="supplementary-material"}) ([@bib21]). Molecular weight was a critical property because molecules larger than 300 Da had poor targetability. Hydrophilicity of molecule also played important role in determining tumor specificity; for example, elongation of one or two methyl groups on the side chain increased log*D* and decreased the tumor targetability. These physicochemical properties had combinatorial effect on the tumor targetability. MW less than 300 Da did not always have good tumor targetability if it also had high log*D* (Ox4). Also, if the molecule had slightly high log*D* with low TPSA and MW (Ox89), it likely also displayed good tumor targetability.

The distribution of tumor-targeting agents also relies on the plasma pharmacokinetics and transport through tumor vasculature into the extravascular tumor tissue ([@bib11]). Plasma protein binding (PPB) greatly impacts the behavior (distribution and elimination) of the drug, where only the unbound fraction is available to interact with the target site ([@bib32]). To have lasting pharmacological effect, a large fraction of the drug must be distributed to the tumorous tissue with high affinity ([@bib11]). Interestingly, Ox61 had the highest unbound fraction compared with all the other drugs in the library. In addition, molecules with similar physicochemical properties as Ox61 but lower TBR had smaller unbound fraction compared with Ox61. This clearly explained why Ox61 outperformed all the other drugs and emphasize that PPB is a critical parameter to determine the availability of drug to the biological target.

Our data clearly show that Ox61 quickly extravasated and accumulated into tumor tissue with higher affinity compared with normal pancreas after intravenous injection ([Figure 4](#fig4){ref-type="fig"}). Physicochemical and pharmacodynamic characteristics including positive charge of Ox61 might facilitate extravasation and accumulation in tumor tissue with the negative charges of the vessel luminal face and molecules in the interstitial space ([@bib6], [@bib2]). The development of targeted NIR fluorescent contrast agents for endocrine tumor is particularly difficult because it requires initial distribution into the endocrine organ while simultaneously localize in higher concentration within the targeting tumor, regardless of anatomic location and barriers to give contrast between the normal tissue ([@bib17], [@bib16], [@bib27]). When bioengineering contrast agents that target tumors by their inherent chemical structures, we must determine the design criteria (i.e., size, charge, and hydrophobicity) of the drug with regard to the plasma pharmacokinetics and physiological barriers to the target tissue. A significant portion of Ox61 injected intravenously in a single formulation was immediately delivered to the tumors, providing unparalleled contrast between the normal pancreas and the pancreatic tumor. To our knowledge, there is no single contrast agent that can highlight tumor within a minute after intravenous injection.

In conclusion, NIR fluorescent intraoperative imaging using Ox61 greatly facilitated the localization of small occult PNET and has the potential to reduce operation times and increase the likelihood of negative margins. Our new technology of drug design for delivering targeted agent can be applied for developing various other tumor targeting agents (i.e., ovarian, breast, thyroid) and can result in immediate detection of tumor upon injection with high specificity, which is difficult to achieve with nanoparticles or proteins and transporter targeting. Furthermore, Ox61 has high potential for accelerated approval by FDA for clinical use of tumor targeting, following the safety and regulatory guideline of MB.

Limitation of the Study {#sec3.1}
-----------------------

Even though we performed extensive *in vivo* and molecular analyses to determine to the mechanism of action allowing PNET targeting by Ox61, we were unable to determine target proteins or transporters on PNET cells. The physicochemical properties of Ox61 led rapid molecular distribution into the tumor site, whereas the retention mechanism on the target needs further investigation.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figures S1--S10
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